Primary spontaneous pneumothorax (PSP) refers to a fracture of the pulmonary parenchyma or visceral pleura, resulting in gas accumulation in the pleural cavity and this may be not be accompanied by underlying lung diseases [1]. PSP is commonly treated with emergency thoracic surgery. The PSP incidence is 7.4–18 of 10,000 persons annually for men and 1.2–6 of 10,000 persons for females [2]. PSP occurs in tall, slender individuals who are male, smoking, and have fibrosis as detected by a chest X-ray. Most PSP symptoms are mild and patients do not seek medical treatment. Thus, the actual PSP incidence may be greater than seen with clinical findings.

Pathogenesis of PSP remains unclear and may arise from terminal airway inflammation [3], genetic factors [4], abnormal fibrous connective tissue [5], abnormal anatomy of the bronchial tree [6], emaciation with large negative intrapleural pressure [7], insufficient blood supply to the apex, low body mass index, and caloric restriction [8], as well as elevated plasma concentrations of aluminum [9]. Pulmonary fibrosis, congenital dysplasia, and inflammation have been thought to be responsible for PSP pathogenesis but little data support these assertions. We measured 3 cytokines (i.e., Krebs Vonden Lungen-6 (KL-6), fibroblast growth factor-10 (FGF-10), and matrix metalloproteinase-9 (MMP-9)) in PSP samples and evaluated their significance on the development and progression of the disease.

**Abstract**

**Objective:** Pathogenesis of primary spontaneous pneumothorax (PSP) is unclear and has been rarely reported in the literature. Thus, we measured expression of Krebs Vonden Lungen-6 (KL-6), fibroblast growth factor-10 (FGF-10), and matrix metalloproteinase-9 (MMP-9) in PSP samples and evaluated their significance on the development and progress of the disease.

**Methods:** Immunohistochemical staining and ELISA were used to measure expression of KL-6, FGF-10, and MMP-9 in the pulmonary bullae and the peripheral normal lung tissue in 24 cases of PSP. Statistical results were analyzed using the Student’s paired t-test.

**Results:** Immunohistochemical data revealed that KL-6 and FGF-10 expression in the pulmonary bullae was significantly higher than in peripheral normal lung tissue, but MMP-9 expression did not differ. ELISA confirmed that KL-6 and FGF-10 expression in the pulmonary bullae was significantly higher than the peripheral normal lung tissue (P < 0.05); but MMP-9 expression again did not differ (P > 0.05).

**Conclusion:** Expression of KL-6 and FGF-10 in pulmonary bullae of PSP patients was significantly higher than in the peripheral normal lung tissue, suggesting that KL-6 and FGF-10 expression in the bullae significantly higher than in normal lung tissue. However, differences in MMP-9 expression again did not differ (P > 0.05).

**Keywords**

Primary spontaneous pneumothorax, Krebs Vonden Lungen-6 (KL-6), Fibroblast growth factor-10 (FGF-10), Matrix metalloproteinase-9 (MMP-9)

**Introduction**

Primary spontaneous pneumothorax (PSP) refers to a fracture of the pulmonary parenchyma or visceral pleura, resulting in gas accumulation in the pleural cavity and this may be not be accompanied by underlying lung diseases [1]. PSP is commonly treated with emergency thoracic surgery. The PSP incidence is 7.4–18 of 10,000 persons annually for men and 1.2–6 of 10,000 persons for females [2]. PSP occurs in tall, slender individuals who are male, smoking, and have fibrosis as detected by a chest X-ray. Most PSP symptoms are mild and patients do not seek medical treatment. Thus, the actual PSP incidence may be greater than seen with clinical findings.

Pathogenesis of PSP remains unclear and may arise from terminal airway inflammation [3], genetic factors [4], abnormal fibrous connective tissue [5], abnormal anatomy of the bronchial tree [6], emaciation with large negative intrapleural pressure [7], insufficient blood supply to the apex, low body mass index, and caloric restriction [8], as well as elevated plasma concentrations of aluminum [9]. Pulmonary fibrosis, congenital dysplasia, and inflammation have been thought to be responsible for PSP pathogenesis but little data support these assertions. We measured 3 cytokines (i.e., Krebs Vonden Lungen-6 (KL-6), fibroblast growth factor-10 (FGF-10), and matrix metalloproteinase-9 (MMP-9)) in PSP samples and evaluated their significance on the development and progression of the disease.

**Materials and Methods**

**Sample sources**

A total of 24 patients (18 males; age range 13–25 years, mean age=17 years) were included and underwent thoracoscopic resection of pulmonary bullae in our hospital from January 1, 2012 to June 30, 2012 due to PSP. All patients had no history of smoking or other comorbidities (such as pulmonary fibrosis or inflammation). Pneumothorax and/or the presence of bullae were confirmed in all patients by chest X-ray or chest computed tomography prior to surgery. Intraoperational pulmonary bullae were confirmed in all patients. Pathological thoracoscopic examination of resected pulmonary bullae was performed and tissue samples were chosen for the experimental group. Controls included normal peripheral lung tissues. All tissues were stored at -80°C.

**Reagents**

Mouse anti-human KL-6 monoclonal antibody, rabbit anti-human FGF-10 polyclonal antibody, and rabbit anti-human MMP-9 polyclonal antibody were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX). Goat anti-mouse/rabbit secondary antibodies and 3,3’- diaminobenzidine (DAB) enhanced liquid substrate kit was purchased from (Beijing Zhong Shan – Golden Bridge Biological Technology Co., Ltd., Beijing, China). KL-6, FGF-10, and MMP-9 enzyme-linked quantitative detection kits were purchased from Shanghai Senxiong Technology Industry Co., Ltd., Shanghai, China).
Total protein quantitative detection kit was purchased from Pierce Biotechnology, Inc. (BCA protein assay kit, Thermo Fisher Scientific, Waltham, MA).

**Immunohistochemical staining**

Tissue samples were post-fixed in formalin solution, followed by paraffin embedding (tissue sections 5µm thickness). All tissue sections were incubated in the oven for 45 min, followed by hydration through an ethanol gradient and ultimately into water. EDTA (pH 8.0) solution was used to heat retrieve the antigen for 18 min, followed by cooling at room temperature and washing. A 3% hydrogen peroxide solution was used to quench endogenous peroxidase. After washing PBS in 2 times, 1:50 dilutions of KL-6, FGF-10, and MMP-1 primary antibodies were added to individual tissue sections and incubated at room temperature for 1 h, followed by PBS washing 3 times. Secondary antibodies were then added to tissue sections and incubated at room temperature for 15 min, followed by PBS washing 3 times. DAB enhanced liquid substrate was used for color development which was terminated by rinsing with water. Tissue sections were counterstained with hematoxylin dye and differentiated with hydrochloric acid alcohol. Ammonium hydroxide solution was used convert hematoxylin staining into a deep purplish blue color. Tissue sections were dehydrated in an ethanol gradient, followed by xylene clearance before mounting with neutral gum. Immunohistochemical staining was examined under light microscopy.

**ELISA**

Tissue samples from the experimental and control groups were thawed on a filter paper to absorb blood and water, weighed, and to each was added 1.5 ml PBS and phenylmethanesulfonylfluoride (PMSF, protease inhibitor) mixture. Tissue homogenization was followed by centrifugation at 4°C to collect the supernatant. In a 96-well plate, precoated with KL-6, FGF-10, or MMP-9 antibody, 100µl of antigen standard or sample supernatant was added per well as detailed in the ELISA kit manual. The 96-well plate was incubated at 37°C for 120 min. After thorough washing, 50µl anti-primary antibody working solution was added into each well and incubated at 37°C for 60 min. After thorough washing, 100µl enzyme-conjugated antibodies was added and incubated at 37°C for 60 min. After thorough washing, 100µl substrate solution was incubated at 37°C for 10 min, followed by reaction termination with 50µl stop solution. Absorbance (optical density, OD) was measured at 450nm. Standard calibration curves were used to estimate of KL-6, FGF-10, and MMP-9 in the samples of both experimental and control groups. Each cytokine was then quantified by dividing the amount of total protein used in each ELISA sample.

**Statistical analysis**

SPSS17.0 software was used for statistical analysis and the Student’s paired t-test was used to analyze data between experimental and control groups. P<0.05 was considered to be statistically significant.

**Results**

**Experimental results of KL-6**

Expression of KL-6 in the experimental group (Figure 1A) was significantly higher than in controls (Figure 1B). Both groups were normally distributed. KL-6 mean concentration was 0.15 ± 0.10 in the experimental group and 0.06 ± 0.02 in the control group. KL-6 in the experimental group was significantly higher than in controls (t = 2.320, P<0.05).

**Experimental results of FGF-10**

Expression of FGF-10 in the experimental group (Figure 2A) was

Figure 1: Representative image of KL-6 IHC staining in the experimental group (positive KL-6 expression is brown; hematoxylin counterstained nuclei are blue) (A) KL-6 expression in the experimental group and (B) in the control group (×200 magnification)

Figure 2: Representative image of FGF-10 IHC staining in the experimental group (positive FGF-10 expression is brown; hematoxylin counterstained nuclei are blue) (A) FGF-10 expression in the experimental group and (B) in the control group (×200 magnification)
FGF-10 is a member of the fibroblast growth factor family and a chemoattractant for epithelial cells. KL-6 is a fibroblast chemoattractant that induces fibroblast migration and aggregation in damaged alveolar space to mediate alveolar fibrosis. KL-6 may also be involved in the formation and development of PSP. Proliferation of fibrous connective tissue leads to alveolar damage which causes scar formation. Scars reduce alveolar elasticity compromising alveolar gas exchange and ultimately forming pulmonary bullae.

KL-6 is a sensitive biomarker of interstitial lung diseases (e.g., idiopathic pulmonary fibrosis, hypersensitivity pneumonitis, and radiation pneumonitis) due to its role in pulmonary fibrosis. KL-6 expression is increased via stimulation of inflammatory cytokines, MMP-9 expands the alveolar cavity and weakens alveolar wall, worsening local bronchial inflammatory responses and causing airflow obstruction. In contrast, in response to inflammatory cytokines, MMP-9 expands the alveolar cavity and weakens alveolar elasticity via damaging alveolar matrix components, resulting in gas retention. Expression of MMP-9 in normal tissue is minimal; whereas MMP-9 expression is increased via stimulation of inflammatory cytokines.

MMP-9 expression is increased via stimulation of inflammatory cytokines. MMP-9 can degrade extracellular matrix components in diverse proteins during inflammation, tissue remodeling, pathophysiological cell migration, angiogenesis, and other processes. Through protein aggregation, MMP-9 directly activates collagenase (MMP-9), ALK-5, and other cytokines, resulting in increased MMP-9 expression. The MMP-9 expression is associated with increased inflammation and collagen deposition.

FGF-10 expression in abnormal tissue induces overgrowth of distal tubules and expansion of epithelial tubules, resulting in developmental defects in different tissue areas, leading to the development of pulmonary bullae.

FGF-10 is necessary for lung-bronchial growth and development. Kim's group used transgenic technology to knock out upstream regulatory factors of FGF-10 in a mouse model. They reported impairment of lung-bronchial development with emphysema-like changes in adult mice. These reports support that abnormal FGF-10 expression leads to abnormal lung-bronchial growth and development. We report that FGF-10 expression in PSP lung lesions was significantly higher than in controls, suggesting that PSP lesions also had abnormal expression of FGF-10 which caused abnormal lung-bronchial growth and development.

MMP-9 is a marker for chronic obstructive pulmonary disease (COPD). Simpson's group collected 100 cases of COPD (experimental group) and 61 healthy volunteers (control group) and measured sputum MMP-9. They report that MMP-9 in the experimental group was significantly higher than in controls (P < 0.05). Chen and co-workers reported in a meta-analysis derived from Pubmed and the CNKI database that there was a significant correlation between MMP-9 expression and the risk of COPD in healthy smokers as controls. Thus, in COPD, with pathological features of chronic inflammation including airway inflammation, pulmonary parenchyma, and pulmonary vessels, MMP-9 may be important in the inflammatory process. Our data did not confirm these findings, however. This may be explained by the fact that PSP inflammation is not mediated by MMP-9 or that the limited occurrence and extent of PSP inflammatory responses may not be detected by our methods. We may require more subjects to observe significant differences in MMP-9 expression between the experimental and control groups. Also, our sample was small, and we may require more subjects to observe significant differences in MMP-9 expression.

At this time, pathogenesis of PSP is not entirely clear. We report...
that KL-6 mediated pulmonary fibrosis and abnormal expression of FGF-10 which led to lung-bronchial congenital abnormalities that may be associated with the incidence of PSP. Our work offers a theoretical basis for the study of PSP pathogenesis. KL-6 and FGF-10 are important markers for interstitial lung disease and asthma via their roles in pulmonary fibrosis and lung development. Therefore, confirmation of the correlation of pathogenesis of PSP and interstitial lung disease and asthma are needed to predict PSP development. We confirmed high expression of KL-6 and FGF-10 in pulmonary bullae but confirmation of differences in serum KL-6 and FGF-10 in PSP patients is needed. To date, PSP diagnosis is made by chest X-ray and CT. Conformation of cytokine expression may help with early diagnosis and prevention of PSP.

References